Science & Enterprise subscription

Follow us on Twitter

  • Many thanks @SciSeeker https://t.co/uQy4yl5pQb
    about 16 hours ago
  • New post on Science and Enterprise: Taking a Break https://t.co/QgH851GMZX #Science #Business
    about 4 days ago
  • Total venture capital funding in the U.S. for first six months of 2019 reached levels not seen since the year 2000,… https://t.co/cGSC6j1Xl8
    about 4 days ago
  • New post on Science and Enterprise: Infographic – U.S. Venture Funds Near 20-Year Highs https://t.co/mIkraoGRAH #Science #Business
    about 4 days ago
  • A set of computational tools developed at Purdue University enables public safety agencies to monitor potentially c… https://t.co/NHSLm9YBBG
    about 5 days ago

Please share Science & Enterprise

Trial Shows Immunotherapies Extend Life with Melanoma

T-cell lymphocyte

First results from a clinical trial show a combination of immunotherapies extends survival among patients with melanoma, but shorter periods for other solid-tumor cancers. . . . → Read More: Trial Shows Immunotherapies Extend Life with Melanoma

Anti-Smoking Ads Not Reaching Most in U.S.

Lit cigarette

A nationwide survey shows a majority of American adults, including half of those who smoke, did not see court-ordered anti-smoking TV or newspaper advertisements. . . . → Read More: Anti-Smoking Ads Not Reaching Most in U.S.

Analysis – Most New Drugs Not Adding Patient Benefits

Tablet with charts

An analysis of drugs approved for use in Germany since 2011 shows no evidence most treatments provide new or added benefits to patients compared to standard care. . . . → Read More: Analysis – Most New Drugs Not Adding Patient Benefits

Immunotherapy Biotech Gains $325M in Venture Funds

Investment graphic

A biotechnology enterprise developing personalized treatments for cancer and infectious diseases is raising $325 million in its second venture funding round. . . . → Read More: Immunotherapy Biotech Gains $325M in Venture Funds

Stem Cell Start-Up Raises $250M in Venture Funds

T-cell lymphocyte

A company begun last year to create cancer therapies from banked, off-the-shelf stem cells is raising $250 million in its first round of venture financing. . . . → Read More: Stem Cell Start-Up Raises $250M in Venture Funds

Company Launches Attacking Cancer Proteins, Lands $67M

Cancer magnified

A new enterprise is starting-up to develop treatments that target cancer-causing proteins considered unreachable with current therapies. . . . → Read More: Company Launches Attacking Cancer Proteins, Lands $67M

Chip Device Tests for Cancer Drug Efficacy, Toxicity

A configurable chip device simulating several human organs is shown in lab tests to simultaneously test cancer drugs for both their efficacy and toxicity. . . . → Read More: Chip Device Tests for Cancer Drug Efficacy, Toxicity

Liquid Biopsy Screening Start-Up Launches, Gains $110M

Blood sample tubes

A new enterprise is starting up, developing early-stage cancer screening with a single blood test, based on research at Johns Hopkins University. . . . → Read More: Liquid Biopsy Screening Start-Up Launches, Gains $110M

Gold Nanoparticles Boost Crispr Delivery

Reza Shabazi and Jennifer Adair

Cancer researchers designed a technique using gold nanoscale particles for safer delivery of edited gene therapies to blood-forming stem cells. . . . → Read More: Gold Nanoparticles Boost Crispr Delivery

Viral Disease Biotech Joins ElevateBio, Gains $120M

T-cells illustration

A biotechnology company developing immunotherapies for viral diseases is joining the ElevateBio consortium providing manufacturing for cell and gene therapies. . . . → Read More: Viral Disease Biotech Joins ElevateBio, Gains $120M